Parlodel
In brief
- In our pharmacy, you can buy Parlodel without a prescription, with delivery across the United Kingdom in 9–21 days; discreet and anonymous packaging is available.
- Parlodel (bromocriptine) is used to treat hyperprolactinaemia, Parkinson’s disease and acromegaly; it is a dopamine D2 receptor agonist that suppresses prolactin secretion, can reduce growth hormone release and improves dopaminergic tone in the CNS.
- Usual dosages vary by condition: hyperprolactinaemia 1.25–2.5 mg once or twice daily, up to 7.5–15 mg/day; acromegaly often 1.25–2.5 mg qd/bid with titration up to 20–30 mg/day; Parkinson’s typically starts 1.25 mg qd/bid and may be titrated to 10–40 mg/day in practice.
- Form of administration: oral tablets, commonly 2.5 mg.
- Onset time: plasma levels rise within 1–2 hours and prolactin suppression can be seen within hours; symptomatic improvement (eg menstrual changes, motor symptoms) may take days to weeks.
- Duration of action: relatively short – multiple daily doses are often needed; the plasma half‑life is approximately 2–8 hours, so clinical effect typically does not last a full day without repeated dosing.
- Alcohol warning: avoid or limit alcohol while taking Parlodel — alcohol increases the risk of dizziness, sedation and orthostatic hypotension.
- The most common side effect is nausea; other frequent effects include headache, dizziness/vertigo, fatigue, orthostatic hypotension and constipation; psychiatric effects (confusion, hallucinations) can occur, especially in the elderly or at high doses.
- Would you like to try Parlodel without a prescription?
Basic Parlodel information
- INN (international nonproprietary name): Bromocriptine
- Brand names available in the United Kingdom: Parlodel; generic bromocriptine
- ATC code: G02CB01 (Bromocriptine)
- Forms and dosages: Tablets 2.5 mg
- Manufacturers in the United Kingdom: Novartis (originator); generic manufacturers
- Registration status in the United Kingdom: Prescription-only medicine, licensed for hyperprolactinaemia, Parkinson’s disease and acromegaly
- OTC / Rx classification: Prescription-only medicine (POM)
Critical warnings and restrictions
Immediate safety priorities for UK patients
Is this medicine safe to start at home?
Bromocriptine (Parlodel) is a prescription-only medicine and is regulated by UK authorities such as the MHRA.
Always follow the directions given by the prescriber and the dispensing pharmacist.
Stop the medicine and seek urgent care if any of the following occur — these may indicate rare but serious cardiac, vascular or neurological events.
- Sudden, severe chest pain.
- New, sudden breathlessness or difficulty breathing.
- Fainting or sudden collapse.
- Severe, persistent vomiting.
- Sudden or severe psychiatric change (new hallucinations, severe agitation, confusion).
- Sudden weakness, numbness, or speech problems suggestive of stroke.
Report suspected adverse drug reactions to the MHRA Yellow Card scheme and inform the prescriber or pharmacist.
Absolute contraindications include uncontrolled hypertension, current or past severe psychotic disorders, known hypersensitivity to bromocriptine or other ergot alkaloids, and use in postpartum women at risk of pre-eclampsia or eclampsia.
Before starting, review the full medication list and current health problems with the prescriber and pharmacist.
- Review concurrent medicines for interactions.
- Monitor blood pressure during dose titration.
- Consider a baseline pregnancy test if relevant.
- Use supervised initiation in elderly patients or those with known cardiovascular disease.
High-risk groups
Who needs extra monitoring?
Elderly patients are at higher risk of orthostatic hypotension, confusion and hallucinations, especially at higher doses or when used for Parkinson’s disease.
People with established cardiac disease, hepatic or renal impairment, a history of peptic ulcer disease, or previous psychiatric illness require caution and closer follow-up.
Children should only be treated under specialist paediatric endocrine or neurology teams.
Pregnancy and breastfeeding require specialist counselling; postpartum use is contraindicated where there is pre-eclampsia or eclampsia risk.
Follow dosing-caution notes and monitoring recommendations when treating high-risk groups.
- BP monitoring frequency: baseline, after each up-titration step, and periodically once stable.
- ECG if there is significant cardiac history or symptoms.
- Liver function tests where hepatic impairment is suspected.
- Prolactin (or GH) levels according to the treating specialty protocol.
Interaction with activities
Will Parlodel affect driving or work?
Common side effects include dizziness, fainting (syncope), visual disturbance and somnolence, particularly during dose titration.
If affected, do not drive or operate machinery until the impairment has resolved.
Under UK law, sustained or unpredictable impairment must be reported to the DVLA where applicable, and to occupational health if work safety is affected.
Employers and drivers should be informed when treatment causes persistent impairment that might affect safety-sensitive duties.
- Avoid driving during dose escalation.
- Avoid working at height while adjusting doses.
- Do not operate heavy machinery until well tolerated.
Q&A — “Can I drive after taking it in the UK?”
Short answer: do not drive if you feel dizzy, drowsy, faint or have visual disturbances.
During dose changes or if side effects occur avoid driving; notify the DVLA or occupational health if impairment continues.
Report adverse events to the MHRA Yellow Card scheme and inform the prescriber or pharmacist.
Usage basics
INN, brand names available in the UK
What names will my prescription show?
The International Nonproprietary Name is Bromocriptine.
In UK practice the originator trade name Parlodel is well known and generic bromocriptine is also available.
- INN: Bromocriptine.
- Common brand names: Parlodel; generic bromocriptine.
- Typical packaging: 2.5 mg tablets in blister packs.
Legal classification
Do I need a prescription?
Parlodel/bromocriptine is prescription-only medicine (POM) across the UK and is subject to MHRA regulation.
NHS prescriptions are issued by GPs, hospital specialists or consultants; community pharmacists dispense and provide counselling.
Electronic prescriptions (EPS) are commonly used.
- Who can prescribe: GP, hospital specialist, or hospital consultant.
- Dispensing safeguards: prescription verification, pharmacist counselling and advice on contraindications/interactions.
Dosing guide
Standard regimens
What starting dose will I be given?
Dosing is indication-specific and usually begins at a low dose with gradual titration to reduce nausea and orthostatic hypotension.
| Condition | Starting dose | Usual maintenance | Max dose |
|---|---|---|---|
| Hyperprolactinaemia | 1.25–2.5 mg once or twice daily | Up to 7.5 mg/day in divided doses | 15 mg/day |
| Acromegaly | 1.25–2.5 mg once or twice daily | Gradual titration, up to 20 mg/day | 30 mg/day |
| Parkinson’s disease (adjunct) | 1.25 mg once or twice daily, titrate | Typical 10–40 mg/day depending on response | Rarely exceed 100 mg/day under specialist care |
Take measures to reduce nausea — dose slowly, consider taking with food and discuss antiemetic options with the prescriber if necessary.
Adjustments for comorbidities
Do doses change if I’m older or unwell?
Elderly patients should start at lower doses and titrate slowly because of increased risk of hypotension and central nervous system effects.
Hepatic or renal impairment requires caution with potentially lower starting doses and closer monitoring; there are no universal formal adjustment rules.
Paediatric treatment is specialist-only and dosing is managed by paediatric endocrine or neurology teams.
Pregnancy and lactation require specialist risk–benefit discussion; avoid postpartum initiation if there is pre-eclampsia/eclampsia risk.
- Checklist: start low and slow in the elderly; monitor BP at each dose increase; consider ECG if cardiac history exists.
Q&A — “What if I miss a dose?”
Take the missed dose as soon as remembered unless it is close to the next scheduled dose.
Do not double doses to catch up.
If vomiting occurs after a dose and absorption is uncertain, contact a pharmacist or GP for advice about the next step.
Interaction chart
Food and drinks
Will alcohol or coffee affect it?
Alcohol can increase drowsiness and worsen orthostatic hypotension when taking bromocriptine.
Caffeine may increase jitteriness but there is no major direct interaction recorded.
Taking the tablet with food often reduces nausea; keep meals consistent during titration.
- Avoid alcohol during dose escalation or if feeling dizzy.
- Small, frequent meals can reduce nausea.
- Discuss antiemetic options with the prescriber if needed.
Common drug conflicts
Which medicines interact with bromocriptine?
| Drug class | Interaction type | Suggested action |
|---|---|---|
| Antipsychotics (dopamine antagonists) | Reduce bromocriptine effect | Review necessity; specialist advice |
| Macrolide antibiotics / CYP inhibitors | May alter levels; potential increased effects | Monitor clinically; adjust dose if required |
| Other ergot alkaloids | Additive ergot toxicity | Avoid co-administration |
| Antihypertensives | Possible additive hypotension | Monitor BP closely during titration |
Ask the pharmacist for a full medication review before starting, and report adverse reactions via the Yellow Card scheme to help track safety signals.
Legal status and availability in the UK
In our online pharmacy, Parlodel is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Mechanism and pharmacology
Simplified explanation
How does bromocriptine work?
Bromocriptine is a dopamine D2 receptor agonist and an ergot derivative that suppresses prolactin secretion from the pituitary gland.
It can also reduce growth hormone secretion in acromegaly and improve dopaminergic tone in the central nervous system for Parkinson’s adjunct therapy.
- Mechanism: Dopamine D2 receptor agonist.
- Clinical effect: Lowers prolactin, can lower GH and modestly affect glucose metabolism.
- Practical implication: Used to treat prolactin-driven amenorrhoea/galactorrhoea, as adjunct in acromegaly and Parkinson’s.
Clinical terms
What about pharmacokinetics and monitoring?
Bromocriptine has a shorter half-life than cabergoline, which explains the need for more frequent dosing in many indications.
It is administered orally in tablet form, commonly 2.5 mg strength in blister packs.
Being an ergot class medication, rare vascular and psychiatric adverse events are possible and require vigilance.
- Monitor: blood pressure, mental state, prolactin or GH levels as per indication, and ECG if cardiac risk is present.
Indications and off-label uses
MHRA-approved uses
What is Parlodel licensed for?
- Hyperprolactinaemia — to suppress prolactin and reverse prolactin-related symptoms.
- Parkinson’s disease — as adjunct therapy to improve motor function.
- Acromegaly — to reduce growth hormone levels as adjunctive therapy.
Off-label practices in NHS and private care
Are there other uses?
Off-label and research uses include investigational metabolic benefits in metabolic syndrome, cluster headache research and psychiatric research in selected contexts.
Off-label prescribing should be specialist-led, with documented informed consent and monitoring.
- Checklist for off-label use: documented rationale, informed consent, monitoring plan, specialist oversight and clear recording in clinical notes.
Alternatives matrix
NHS prescribing alternatives
Which drugs are commonly chosen instead of Parlodel?
| Drug | Indication | Typical dose | Advantages | Key risks |
|---|---|---|---|---|
| Cabergoline (Dostinex) | Hyperprolactinaemia, Parkinson’s adjunct | Low-dose weekly dosing for hyperprolactinaemia | Longer half-life, often better tolerated, less frequent dosing | Cardiac valvulopathy risk at high cumulative doses; specialist monitoring |
| Quinagolide (Norprolac) | Hyperprolactinaemia | Once-daily dosing where available | Once-daily dosing option | Availability varies; similar dopamine agonist risks |
| Dopamine agonist combinations | Parkinson’s disease (adjunct) | Variable | Individualised motor symptom control | Complex interactions and cumulative side effects |
Choose Parlodel when cabergoline is unsuitable, or when quick prolactin suppression with a tried agent is required.
Pros and cons checklist
- Efficacy: effective for prolactin suppression and symptomatic control.
- Side-effect profile: higher early nausea and orthostatic hypotension compared with cabergoline.
- Dosing frequency: usually more frequent dosing than cabergoline.
- Pregnancy plans: consider alternatives or specialist advice if pregnancy is planned.
- Cardiac history: weigh valvular and vascular risks and monitor accordingly.
Common questions
What do patients ask most often?
- How soon will prolactin fall? — Prolactin often falls within days to weeks; levels should be monitored as instructed by the treating clinician.
- Can I stop when symptoms improve? — Only stop after clinician review and planned tapering; do not stop abruptly without medical advice.
- Is it safe during breastfeeding? — Bromocriptine is sometimes used to suppress lactation; discuss risks and benefits with obstetrician or midwife before use.
- How do I report side effects? — Report side effects to the MHRA Yellow Card scheme and inform the prescriber and pharmacist.
For further NHS guidance consult local specialist services or NHS.uk for condition-specific pathways.
Registration and regulation
MHRA approval process
How is Parlodel regulated?
The MHRA oversees product licensing, labelling and post-marketing safety for medicines supplied in the UK.
Consult the Summary of Product Characteristics (SPC), Patient Information Leaflet (PIL) and MHRA alerts for the most up-to-date guidance.
- Regulatory documents: SPC, PIL, MHRA safety updates and alerts.
NHS prescribing framework
Who starts treatment and who continues it?
Prescribing may be initiated by a GP, specialist or hospital team depending on indication; hospital specialists commonly initiate for acromegaly and Parkinson’s disease.
Shared-care protocols and local formularies may determine ongoing prescribing responsibilities.
- Prescriber checklist: baseline tests (BP, pregnancy status where relevant), monitoring schedule and clear shared-care agreements if required.
Storage and handling
UK household storage
How should Parlodel be stored at home?
Store at room temperature and protect from excess moisture and heat.
Keep tablets in their original blister packaging until use and protect from light.
Avoid storing medicine in bathrooms or windowsills in damp UK homes; use an airtight container if humidity is a concern.
- Household tips: keep in a cool, dry place, away from children and pets.
- Travel precautions: carry in original packaging with prescription if travelling.
Guidance from NHS and pharmacists
When should I throw it away?
Check expiry dates and return unused or expired medication to a pharmacy for safe disposal.
Do not share medication with others and store securely away from children.
- Disposal checklist: take-back to pharmacy; do not dispose in household waste.
- Transport checklist: keep at room temperature and in original packaging while travelling.
Guidelines for proper use
UK pharmacist counselling style
What will the pharmacist tell me when dispensing?
Confirm the indication and dose, typically 2.5 mg tablets in many dispensing situations.
Review contraindications and allergies, discuss common side effects and practical management, and outline missed-dose rules.
Explain driving and workplace safety warnings and provide written information (PIL) alongside verbal advice.
- Counselling script items: indication, dose schedule, expected side effects (nausea, dizziness), when to seek urgent care, missed-dose instructions, and monitoring plan.
- Provide a patient handout summarising BP monitoring, adverse symptom red flags and Yellow Card reporting.
NHS patient safety advice
What follow-up will I have on the NHS?
Pre-initiation screening should include blood pressure, psychiatric history and pregnancy status where relevant.
Suggested follow-up timeline: review at two weeks after initiation, then around three months, and thereafter as clinically indicated.
Report adverse effects to the MHRA Yellow Card scheme and keep planned medication reviews at least annually or sooner if doses change.
- Safety checklist: baseline checks, follow-up blood tests for prolactin/GH where indicated, documented monitoring plan and shared decision-making.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Bristol | England | 9–21 days |
| Newcastle | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Norwich | England | 9–21 days |
| Plymouth | England | 9–21 days |
Final notes
Parlodel (bromocriptine) remains a useful, established dopamine agonist for several endocrine and neurological indications.
Prescribers should balance efficacy, side-effect profile and patient preferences when selecting between bromocriptine and alternatives such as cabergoline or quinagolide.
Patients should keep an up-to-date medication list, attend scheduled monitoring and report worrying symptoms immediately to their prescriber or via the MHRA Yellow Card scheme.
Seek pharmacist counselling when collecting Parlodel or bromocriptine tablets.